Showing results (1981-1990 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 12, 2000
Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholineM Y Pushkareva, S L Wannberg, A S Janoff, et al.
Cancer Immunology, Immunotherapy : CII|January 12, 2000
MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccinesB Acres, V Apostolopoulos, J M Balloul, et al.
Cancer Immunology, Immunotherapy : CII|January 12, 2000
Antitumour activity of a chimeric antibody against the leucocyte antigen CD48H Sun, J C Biggs, G M Smith
Cancer Immunology, Immunotherapy : CII|November 7, 1999
Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patientsS Goto, M Sato, R Kaneko, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 1999
Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinomaA Hjelm Skog, P Ragnhammar, J Fagerberg, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 1999
Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cellsS Cappello, N X Liu, C Musselli, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 1999
Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009R F Holcombe, J Jacobson, S R Dakhil, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neuV Pullarkat, Y Deo, J Link, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
Lack of evidence for an immunosuppressive role for MUC1S Paul, N Bizouarne, A Paul, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1995
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19L T Vlasveld, A Hekman, F A Vyth-Dreese, et al.
Pageof 652